Chimerix Osake

Chimerix Termiini P/E

Delisted·17.4.2025

Forward P/E -suhde yhtiöstä Chimerix (CMRX) 26.8.2026 päivämäärällä on −9,06. Edellisenä vuonna Forward P/E -suhde oli −9,76 — muutos −7,12 % (korkeampi).

Termiini P/E

−9,06

YoY

−7,12%

Viimeksi päivitetty:

Forward P/E -suhde yhtiöstä Chimerix on 2026 −9,06 . Forward P/E -suhde yhtiöstä Chimerix oli 2025 −9,76 . Se laskee −7,12% korkeampi edelliseen vuoteen verrattuna.

Chimerix Termiini P/E historia

  • 3 vuotta

  • 10 vuotta

  • 25 vuotta

  • Maksimi

Termiini P/E
Date
Termiini P/E
1.1.2017
−11,29 USD
1.1.2018
−11,53 USD
1.1.2019
−4,61 USD
1.1.2020
−19,02 USD
1.1.2021
−3,13 USD
1.1.2022
4,65 USD
1.1.2023
−9,76 USD
1.1.2024
−9,06 USD
Chimerix Termiini P/E historia
VUOSITermiini P/EYoY
−9,06−7,12%
−9,76−309,72%
4,65−248,57%
−3,13−83,53%
−19,02+312,22%
−4,61−59,99%
−11,53+2,17%
−11,29+7,62%
−10,49+53,65%
−6,83−49,47%
−13,51
Access this data via the Eulerpool API

Chimerix Osakeanalyysi

Mitä Chimerix tekee? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Chimerix osakkeesta

Yhtiön Chimerix Forward P/E -suhde on −9,06 vuonna 2026.

Forward P/E -suhde yhtiöstä Chimerix muuttui arvosta −9,76 arvoon −9,06, mikä edustaa −7,12 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää Forward P/E -suhde Chimerix:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Forward P/E käyttää arvioituja tulevia voittoja osakkeen arvostukseen. Pienempi forward P/E peräkkäiseen P/E:hen verrattuna viittaa analyytikkojen odottavan tuloksen kasvua.

Arvioidakseen Forward P/E -suhde:n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja Forward P/E -suhde:lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata Forward P/E -suhde:n Chimerix alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Chimerix

Kaikki tunnusluvut — Chimerix